U.S. markets open in 7 hours 8 minutes
  • S&P Futures

    3,836.25
    +17.00 (+0.45%)
     
  • Dow Futures

    31,879.00
    +103.00 (+0.32%)
     
  • Nasdaq Futures

    12,381.00
    +83.75 (+0.68%)
     
  • Russell 2000 Futures

    2,209.70
    +8.90 (+0.40%)
     
  • Crude Oil

    64.68
    -0.37 (-0.57%)
     
  • Gold

    1,689.10
    +11.10 (+0.66%)
     
  • Silver

    25.39
    +0.12 (+0.48%)
     
  • EUR/USD

    1.1869
    +0.0017 (+0.14%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3858
    +0.0036 (+0.26%)
     
  • USD/JPY

    108.9890
    +0.0880 (+0.08%)
     
  • BTC-USD

    53,742.37
    +3,037.27 (+5.99%)
     
  • CMC Crypto 200

    1,082.66
    +58.46 (+5.71%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Pfizer is Yahoo Finance Premium’s investment idea of the day

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Yahoo Finance’s Kristin Myers and Jared Blikre discuss Yahoo Finance Premium’s investment idea of the day.

Video Transcript

KRISTIN MYERS: And next up, I know that you're tracking Yahoo Finance Premium's Investment Idea of the Day, which is a buy call on Pfizer. So what's behind that bullish outlook?

JARED BLIKRE: Well, let's take a look. This comes by way of Argus Research. This is a fundamental report on Pfizer. And you can see there the stock really hasn't done much over the last year. It's down about 5%. But let's take a look at some of their reasoning here.

So they're saying they're maintaining their $55 price target with the reasoning that Pfizer is scaling up manufacturing to meet its commitment to deliver 2 billion doses of its coronavirus vaccine by the end of the year. Management projects approximately $15 billion in 2021 revenue from the vaccine, making it by far the largest product in their portfolio.

However, we think the market is underestimating the sustainability of the COVID-19 vaccine franchise and its revenue contribution beyond 2021. We believe that this revenue will prove sustainable based on the company's ability to use the mRNA platform to develop vaccine booster shots and address new virus variants, as well as to create treatments for other conditions. So there you have it there, Kristin.